Kurtz T O, Winston D J, Bruckner D A, Martin W J
Antimicrob Agents Chemother. 1981 Aug;20(2):239-43. doi: 10.1128/AAC.20.2.239.
The in vitro synergistic activities of moxalactam, cefoperazone, or cefotaxime in combination with amikacin or piperacillin were compared against aminoglycoside-susceptible and aminoglycoside-resistant isolates of Pseudomonas aeruginosa and Serratia marcescens by the checkerboard agar dilution method. All antimicrobial combinations demonstrated some synergy, and no antagonism was observed. Moxalactam plus amikacin and piperacillin plus amikacin were most frequently synergistic (two-thirds of the isolates inhibited synergistically by each combination), whereas combinations of moxalactam, cefotaxime, or cefoperazone with piperacillin were synergistic against only 18 to 25% of the isolates. Moxalactam plus amikacin was the combination most often synergistic for amikacin-susceptible P. aeruginosa, and piperacillin plus amikacin was the combination most frequently synergistic for amikacin-resistant P. aeruginosa and amikacin-susceptible S. marcescens. These results demonstrate frequent in vitro synergistic activity between the new beta-lactam agents and amikacin (especially moxalactam or piperacillin with amikacin), but comparative clinical trials are needed to establish the relative efficacy and toxicity of these combinations.
采用棋盘琼脂稀释法，比较了羟羧氧酰胺菌素、头孢哌酮或头孢噻肟与阿米卡星或哌拉西林联合应用对氨基糖苷类敏感及耐药的铜绿假单胞菌和粘质沙雷氏菌的体外协同活性。所有抗菌药物组合均显示出一定的协同作用，未观察到拮抗作用。羟羧氧酰胺菌素加阿米卡星以及哌拉西林加阿米卡星的协同作用最为常见（每种组合能协同抑制三分之二的分离菌株），而羟羧氧酰胺菌素、头孢噻肟或头孢哌酮与哌拉西林的组合仅对18%至25%的分离菌株具有协同作用。羟羧氧酰胺菌素加阿米卡星是对阿米卡星敏感的铜绿假单胞菌最常出现协同作用的组合，哌拉西林加阿米卡星是对阿米卡星耐药的铜绿假单胞菌和阿米卡星敏感的粘质沙雷氏菌最常出现协同作用的组合。这些结果表明新型β-内酰胺类药物与阿米卡星（尤其是羟羧氧酰胺菌素或哌拉西林与阿米卡星）之间在体外常有协同活性，但需要进行比较性临床试验以确定这些组合的相对疗效和毒性。
